the impact of CDI on mortality is unclear. CDI was associated with significantly higher mortality within 180 days of infection in 2 studies, 8, 18 but Willems et al 14 found no difference in overall survival between CDI cases and controls within 2 years of transplantation.
Additionally, variations in study design make it difficult to draw firm conclusions about the morbidity and mortality associated with CDI after allogeneic HCT and lung transplantation. A better understanding of the epidemiology and outcomes of CDI among allogeneic HCT and lung transplant recipients would help clinicians treat patients appropriately and help guide infection prevention priorities.
The purpose of this study was to describe and compare the incidence and outcomes of CDI after allogeneic HCT and lung transplantation, using a multicenter, prospective study design. This study was performed in conjunction with the Organ Transplant Infection
Prevention and Detection Project (OTIP) of the Centers for Disease
Control and Prevention (CDC). OTIP was a prospective cohort study of all proven and probable invasive fungal infections in patients undergoing allogeneic HCT or lung transplantation (lung and allogeneic HCT transplants were selected for analysis because of the higher rates of invasive infections among these patients); however, data on other infections, including CDI, were collected as well, providing a prospective opportunity to study CDI after lung and allogeneic HCT transplant. 
| PATIENTS AND ME THODS
Six
| Data collection
Participants underwent clinical assessments at enrollment and weekly during their transplant hospitalization. After discharge, participants were contacted by phone weekly up to 12 weeks posttransplant. After 12 weeks, participants were contacted monthly.
If readmitted to the hospital, participants were followed weekly until discharge. Participants were followed up for 2.5 years posttransplant for readmissions, infections, and other outcomes.
Demographic data collected at enrollment included age, sex, 
| Data analyses
Clostridium difficile infection cases were included if they occurred any time within 365 days post-transplant. 
| RE SULTS
A total of 614 patients met inclusion criteria for this study and were included in analyses. Lung transplant recipients accounted for 37% of the enrolled patients (N = 229) and allogeneic HCT recipients accounted for 63% (N = 385). One hundred and fifty patients developed CDI within 365 days of transplant: 30 (20% of CDIs) among lung transplant recipients (incidence 13.1%) and 120 (80% of CDIs) among allogeneic HCT recipients (incidence 31.2%).
Clostridium difficile infection incidence and time to infection
in lung transplant recipients is shown in Table 1 and in allogeneic HCTs in Table 2 . Site A enrolled 75% of the lung transplant pa- vs 90 days; P = .037; Figure 2 ). 
F I G U R E 1 STROBE diagram of study population
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TA B L E 1 Clostridium difficile infections (CDI) in 229 lung transplant recipients
Patient characteristics associated with CDI after lung transplantation are shown in Table 3 and after allogeneic HCT are shown in Table 4 . Among lung transplant recipients only renal failure was significantly associated with CDI, but the numbers were very small.
After allogeneic HCT, patients with CDI were more likely than uninfected patients to have received myeloablative conditioning (61% vs 38%; P = .003) and high dose dexamethasone (20% vs 13%; P = .053).
Other cardiovascular disease was the only comorbidity that was more common among CDI cases than uninfected HCT recipients (29% vs 18%; P = .015), and lack of a preexisting comorbid disease was more common among uninfected persons than CDI cases (46% vs 31%; P = .004). These relationships were primarily driven by site F, which enrolled 50% of the allogeneic HCTs. When site F was removed from analyses, those 2 comorbidity variables were no longer statistically significant (data not shown). By contrast, when site F was excluded, myeloablative conditioning remained associated with CDI: 86% of cases received myeloablative conditioning vs 68% of controls (P = .01). Any GVHD in the previous 30 days was more common among CDI cases than controls (23% vs 12%; P = .003). History of a symptomatic urinary tract infection (UTI) in the 30 days before the index date was more common among CDI cases than uninfected persons, although the difference was of borderline significance (6% vs 2%, P = .06).
Among lung transplant recipients, several outcomes (renal failure, BSI, and pneumonia) occurred significantly more often among CDI cases than controls in the 30 days post-index date (P < .05 for all; Table 3 ). Notably, 27% of CDI cases experienced a BSI during the 30 days post-index date. Among the allogeneic HCT recipients, CDI cases were more likely than controls to have any GVHD during the 30 days post-index date (40% vs 27%; P = .009; Table 4 ).
Survival within 180 days after CDI/index date is shown in Among patients who had died by 180 days post-index date, the underlying disease was the cause of death among 27% of allogeneic HCT recipients and 8% of lung transplant recipients (P = .07), and any infection was the cause of death among 21% of the allogeneic HCT recipients and 32% of the lung transplant recipients (P = .21).
| D ISCUSS I ON
We compared the epidemiology of CDI in lung transplant and allogeneic HCT recipients. Overall, CDI is common in both populations, but the incidence among allogeneic HCT recipients is more than 2 times higher than the incidence of CDI in lung transplant recipients.
The epidemiology of CDI after lung transplantation is unclear, and the varying duration of follow-up periods in previous studies make it difficult to make comparisons among studies. CDI incidence has been estimated in the range of 7%-31%, 20 and a recent metaanalysis reported the pooled prevalence of CDI at 10.8%, but the duration of follow-up varied by study. 21 We found the median time from transplant to CDI was significantly shorter among allogeneic HCT recipients than lung transplant recipients. This is likely due in part to the comparatively greater immunosuppression caused by allogeneic HCT conditioning regimens, with subsequent prolonged neutropenia, mucositis, and intense antimicrobial exposures. Notably, CDI cases among allogeneic HCT recipients were more likely than uninfected recipients to have received myeloablative conditioning or high dose dexamethasone. The relationship between myeloablative conditioning and CDI in HCT recipients has been noted previously. 7, 11 The underlying biological mechanism behind this relationship may be 2-fold: myeloablative conditioning increases neutropenia, damages the gut mucosa, and is associated with a higher risk of infection in the pre-engraftment period (and thus exposure to broad spectrum antimicrobials) vs non-ablative conditions; all of these may increase risk of CDI. Although antimicrobial usage data were not available for these analyses, we did have prospectively collected data on other infections among the transplant recipients, which can be used as a surrogate marker for antimicrobial use. 25 Additionally, transplant recipients, particularly allogeneic HCT, have almost universal exposure to antimicrobials. Among the allogeneic HCT recipients, symptomatic UTI was a borderline risk factor for CDI. UTIs are often treated with antimicrobials such as fluoroquinolones or cephalosporins, which in turn may increase the risk of CDI. An analysis using Medicare data found that UTIs were responsible for a greater population attributable risk fraction of CDI cases than any other type of infection, 25 and they may be a useful antimicrobial stewardship target.
TA B L E 3 Variables associated with
We found mortality within 180 days of CDI/index date to be significantly higher in the allogeneic HCT population but not the lung transplant population. CDI was not associated with increased risk of mortality within the first 30 days, but mortality was has been suggested previously with CDI and sepsis. 26 Overall, our data suggest that CDI likely increases mortality in allogeneic HCT recipients, while more data are needed on CDI and mortality after lung transplantation.
TA B L E 4 Variables associated with
There are several limitations to this study. Because OTIP's original focus was on fungal infections, not CDI, data on antimicrobials were not collected. Stool samples were not collected, so we were unable to evaluate colonization with C. difficile. A variety of C. difficile diagnostic tests were used at the participating sites, and these may affect CDI rates. 27 Additionally, CDI epidemiology and C. difficile diagnosis have continued to change since this study was performed; for example, use of molecular diagnostics has increased. 27 Finally, this study was not designed for a detailed analysis of the relationship between CDI and GVHD. This relationship is complex, and previous research suggests GVHD, which is associated with loss of a healthy gut microbiome, may be both a risk factor and outcome of CDI. 6, 7, 24, [28] [29] [30] This deserves additional study. Despite these limitations, this analysis has several strengths, including a prospective, 
